{"denoms":[{"counts":[{"groupId":"BG000","value":"31"}],"units":"Participants"}],"groups":[{"description":"Pemetrexed 500 mg/m2 intravenous (IV) every 21 days for 6 cycles","id":"BG000","title":"Pemetrexed"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"35.7","upperLimit":"77.5","value":"62.7"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"27"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30"}]}],"title":"Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Hispanic"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"Spain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Denmark"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Germany"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}]}],"title":"Non-Small Cell Lung Cancer (NSCLC)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Mesothelioma"}],"description":"Diagnosis of Non-Small Cell Lung Cancer (NSCLC) and mesothelioma were determined by each individual investigator.","paramType":"NUMBER","title":"Diagnosis","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"Stage III (locally advanced disease)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"18"}]}],"title":"Stage IV (metastatic disease)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Unknown"}],"description":"Stage means how big the tumor is and how far it has spread. Stages range from 0 (not spread) to IV (spread throughout the body).","paramType":"NUMBER","title":"Disease Stage","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"0 - Fully Active"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"1 - Ambulatory, Restricted Strenuous Activity"}],"description":"Classifies patients according to their functional impairment. Scores range from 0 (Fully Active) to 5 (Death).","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}],"title":"Mild"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"Moderate"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Severe"}],"description":"Mild = (1) pleural effusion detectable on radiological imaging, but less than moderate; (2) ascites detectable only by radiological imaging. Moderate = (1) pleural effusion less than 1/3 of the way up the thorax on 1 side on imaging and obscuring the entire hemidiaphragm on that side; (2) ascites detectable on physical exam (that is, fluid wave is palpable). Severe = (1) pleural effusion more than 1/3 of the way up the thorax on imaging; (2) ascites visibly detectable.\n\nFor Moderate Fluid Severity, there were 13 patients with pleural effusion and 1 patient with ascites.","paramType":"NUMBER","title":"Fluid Severity","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Cytological"},{"categories":[{"measurements":[{"groupId":"BG000","value":"25"}]}],"title":"Histopathological"}],"paramType":"NUMBER","title":"Primary Basis for Diagnosis","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30"}]}],"title":"Pleural Effusion"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Ascites"}],"paramType":"NUMBER","title":"Type of Third-Space Fluid","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1.4","upperLimit":"2.3","value":"1.8"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Body Surface Area","unitOfMeasure":"meters squared (m^2)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"147.0","upperLimit":"189.0","value":"171.0"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Height","unitOfMeasure":"centimeters (cm)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"47.9","upperLimit":"100.0","value":"68.0"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Weight","unitOfMeasure":"kilograms (kg)"}]}